WO1999021549A1 - Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases - Google Patents

Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases Download PDF

Info

Publication number
WO1999021549A1
WO1999021549A1 PCT/KR1998/000324 KR9800324W WO9921549A1 WO 1999021549 A1 WO1999021549 A1 WO 1999021549A1 KR 9800324 W KR9800324 W KR 9800324W WO 9921549 A1 WO9921549 A1 WO 9921549A1
Authority
WO
WIPO (PCT)
Prior art keywords
hesperidin
hesperetin
composition
mammal
cholesterol
Prior art date
Application number
PCT/KR1998/000324
Other languages
French (fr)
Inventor
Song Hae Bok
Tae Sook Jeong
Myung Sook Choi
Surk Sik Moon
Yong Kook Kwon
Eun Sook Lee
Byung Hwa Hyun
Yang Kyu Choi
Chul Ho Lee
Ki Hwan Bae
Yong Bok Park
Jun Sung Lee
Kwang Hee Son
Byoung Mog Kwon
Young Kook Kim
Doil Choi
Sung Uk Kim
Ingyu Hwang
Jung Ah Ahn
Young Bae Park
Hyo Soo Kim
Seong Choon Choe
Original Assignee
Korea Institute Of Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019970055578A external-priority patent/KR19990034089A/en
Priority claimed from KR1019980010888A external-priority patent/KR19990076178A/en
Priority claimed from KR1019980012411A external-priority patent/KR19990079683A/en
Priority claimed from KR1019980013283A external-priority patent/KR19990080214A/en
Application filed by Korea Institute Of Science And Technology filed Critical Korea Institute Of Science And Technology
Priority to EP98951777A priority Critical patent/EP1063988A1/en
Priority to CA002307890A priority patent/CA2307890A1/en
Priority to JP2000517707A priority patent/JP2001520993A/en
Publication of WO1999021549A1 publication Critical patent/WO1999021549A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/56—Flavouring or bittering agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • HESPERIDIN AND HESPERETIN AS INHIBITOR OF ACYL COA- CHOLESTEROL-O-ACYLTRANSFERASE, INHIBITOR OF MACROPHAGE- LIPID COMPLEX ACCUMULATION ON THE ARTERIAL WALL AND PREVENTIVE OR TREATING AGENT FOR HEPATIC DISEASES
  • the present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA- cholesterol-o-acyltransferase (ACAT), inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.
  • ACAT acyl CoA- cholesterol-o-acyltransferase
  • Acyl CoA-cholesterol-o-acyltransferase(ACAT) promotes the esterification of cholesterol in blood.
  • Foam cells are formed by the action of ACAT and contain a large amount of cholesterol ester carried by low density lipoproteins .
  • the formation of foam cells on the wall of artery increases with the ACAT activity, and, accordingly, an inhibitor of ACAT may also be an agent for preventing atherosclerosis.
  • an inhibitor of ACAT may also be an agent for preventing atherosclerosis.
  • the blood level of LDL- cholesterol can be reduced by inhibiting the ACAT activity(Witiak, D. T. and D. R. Feller (eds .) , Anti- Lipidemic Drugs; Medicinal, Chemical and Biochemical Aspects, Elsevier, ppl59-195 ( 1991 ) .
  • deterioration of hepatic functions may occur due to an excessive intake of alcohol or foods having a high lipid content, or an infection of hepatitis B or C virus, and it may develop into hepatitis, hepatocirrhosis or hepatic cancer.
  • the excessive intake of fat-containing foods and alcohol causes fatty liver wherein a large amount of lipids is deposited in the liver tissue and the levels of serum GOT(glutamate- oxaloacetate transaminase) , GPT(glutamate-pyruvate transaminase) and ⁇ -GTP( ⁇ -glutamyl transpeptidase) are elevated(T. Banciu et al . , Med. Interne. , 20, 69-71(1982); and A. Par et al., Acta. Med. Acad. Sci. Hung., 33, 309- 319(1976) ) .
  • Lovastatin® a HMG-CoA reductase inhibitor named Lovastatin® has been developed and marketed by Merck Co., U.S.A.
  • this medicine is known to induce adverse side effect of increasing creatin kinase in the liver.
  • Hesperidin C 28 H 34 0 15 , M.W. : 610.55
  • hesperetin C 16 H 14 0 6 , M.W. : 302.27
  • hesperetin C 16 H 14 0 6 , M.W. : 302.27
  • hesperidin or hesperetin has capillary-enhancing, permeability-reducing, anti-platelet aggregation, anti-inflammation, anti-viral, and blood- pressure and cholesterol lowering activities (Meyer, 0. C, Angiology, 45, 579-584(1994); Struck ann, J. R. , et al . , Angiol. , 45, 419-428(1994); Matsubara, Y., et al . , Japan Organic Synthesis Chem. Association Journal, 52 , 318-327(1994. Mar.); Galati, E. M. , et al., Farmaco .
  • Another object of the present invention is to provide a novel use of hesperidin or hesperetin for inhibiting the ACAT activity in a mammal .
  • Another object of the present invention is to provide a novel use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the endothelial wall of an artery in a mammal.
  • a further object of the present invention is to provide a novel use of hesperidin or hesperetin for preventing or treating hepatic diseases in a mammal.
  • Figs. 1A, IB and 1C show the arteries of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively;
  • Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively.
  • hesperidin or hesperetin for inhibiting the acyl-CoA cholesterol-o-acyltransferase (ACAT) activity in a mammal.
  • ACAT acyl-CoA cholesterol-o-acyltransferase
  • hesperidin or hesperetin for inhibiting the accumulation of macrophage- lipid complex on the endothelial wall of an artery in a mammal.
  • hesperidin or hesperetin for preventing or treating hepatic diseases in a mammal .
  • Hesperidin and hesperetin may be extracted from the peel of citrus or synthesized according to the process described by Zemplen, Bognar, Ber . , 75 , 1043(1943) and Seka, Prosche, Monatsh. , 69 , 284(1936). Further, hesperetin can be prepared by the hydrolysis of hesperidin.
  • Hesperidin or hesperetin exerts an inhibitory effect on the ACAT activity and the accumulation of macrophage-lipid complex on the endothelial wall of an artery, and a preventive or treating effect on hepatic diseases at a dose of 0.1 mg/kg/day or more, the inhibitory effect increasing with the dose thereof.
  • hesperidin or hesperetin shows little toxicity or mitogenicity in tests using mice. More specifically, hesperidin or hesperetin exhibits no toxicity when it is orally administered to a mouse at a dose of 100 mg/kg, which corresponds to an oral administration dose of 3 to 10 g/kg body weight of hesperidin or hesperetin for a person weighing 50 kg. Further, hesperidin and hesperetin exert no adverse effects on the liver function.
  • the present invention also provides a pharmaceutical composition for inhibiting the ACAT activity and accumulation of macrophage-lipid complex on the endothelial wall of an artery, and for preventing or treating hepatic diseases, which comprise hesperidin or hesperetin as an active ingredient and pharmaceutically acceptable excipients, carriers or diluents.
  • a pharmaceutical formulation may be prepared in accordance with any of the conventional procedures.
  • the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient.
  • the formulations may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.
  • Suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates , talc, magnesium stearate and mineral oil.
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.
  • the pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction.
  • a typical daily dose of hesperidin or hesperetin may range from about 0.1 to 100 mg/kg body weight, preferably 3 to 10 mg/kg body weight, and can be administered in a single dose or in divided doses.
  • the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.
  • hesperidin or hesperetin can be incorporated in foods or beverages, as an additive or a dietary supplement, for the purpose of inhibiting the ACAT activity, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium and/or preventing or treating hepatic diseases.
  • the foods or beverages may include meats; juices such as a vegetable juice(e.g., carrot juice and tomato juice) and a fruit juice(e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice); chocolates; snacks; confectionery; pizza; foods made from cereal flour such as breads, cakes, crackers, cookies, biscuits, noodles and the likes; gums; dairy products such as milk, cheese, yogurt and ice creams; soups; broths; pastes, ketchups and sauces; teas; alcoholic beverages; carbonated beverages such as Coca-Cola® and Pepsi-Cola®; vitamin complexes; and various health foods.
  • juices such as a vegetable juice(e.g., carrot juice and tomato juice) and a fruit juice(e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice)
  • chocolates e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice
  • chocolates e.g., orange juice, grape juice, pineapple juice
  • the content of hesperidin or hesperetin in a food or beverage may range from 0.01 to 5% by weight.
  • the beverage according to the present invention may comprise 200 to 10,000 mg of hesperidin or hesperetin per 1000 ml of the beverage.
  • hesperidin or hesperetin can be used as an effective, non-toxic pharmaceutical agent for inhibiting ACAT activity, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and/or preventing or treating hepatic diseases.
  • the peels of tangerines (Cheju Island, Korea), citrons (Jeollanamdo, Korea), and oranges, grapefruits and lemons (California, CA, U.S.A.) were dried at a room temperature and powdered to a particle size ranging from 100 to 200 ⁇ m.
  • 50 iru ⁇ of methanol was added to 500 mg each of the citrus peel powder and extracted in a water bath at 50 °C for 6 hours. The extract thus obtained was cooled and filtered, and then methanol was added to the filtrate to a volume of 50 m£ .
  • the eluates were detected at 280 nm with UV-VIS spectrophotometer and the content of hesperidin was calculated by comparing the areas of HPLC profiles of the citrus peel extract and the standard solution.
  • the content(%) of hesperidin in various citrus peel extracts is shown in Table I.
  • mice 7 to 8 week-old, specific pathogen-free ICR female mice (6 heads) each weighing about 25 to 29 g and male mice (6 heads) each weighing about 34 to 38 g were bred under a condition of temperature 22 ⁇ 1°C, moisture 55 ⁇ 5 % and photoperiod 12L/12D.
  • Fodder(Cheiljedang Co., mouse and rat fodder) and water were sterilized and fed to the mice.
  • Hesperidin or hesperetin was dissolved in 0.5 % Tween 80 to a concentration of 100 mg/ml , and the solution was orally administered to the mice in an amount of 0.2 ml per 20 g of mouse body weight.
  • mice All the mice were alive at day 10 and hesperidin or hesperetin showed no toxicity at a dose of 1,000 mg/kg.
  • the autopsy revealed that the mice did not develop any pathological abnormality, and no weight loss was observed during the 10 day test period. Accordingly, it was concluded that hesperidin or hesperetin is not toxic when orally administered to an animal.
  • the rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the three groups in terms of the feed ingestion amount and the weight gain.
  • the effect of administering hesperidin or hesperetin to rats on the plasma cholesterol and neutral lipid content was determined as follows.
  • liver tissue To determine the effects of hesperidin and hesperetin feeding to rats on the activity of ACAT, microsomes were separated from the liver tissue to be used as an enzyme source.
  • the rats of the three groups prepared in Example 3 were sacrificed by decapitation and the livers were excised. 1 g each of the livers was homogenized in 5 ml of homogenization medium(0.1 M KH 2 P0 4 , pH 7.4 , 0.1 mM EDTA and 10 mM ⁇ -mercaptoethanol) . The homogenate was centrifuged at 3,000xg for 10 min. at 4°C and the supernatant thus obtained was centrifuged at 15,000xg for 15 min. at 4°C to obtain a supernatant.
  • homogenization medium 0.1 M KH 2 P0 4 , pH 7.4 , 0.1 mM EDTA and 10 mM ⁇ -mercaptoethanol
  • the supernatant was put into an ultracentrifuge tube(Beckman) and centrifuged at 100,000xg for 1 hour at 4°C to obtain microsomal pellets, which were then suspended in 3 ml of the homogenization medium and centrifuged at 100,000xg for 1 hour at 4°C.
  • the pellets thus obtained were suspended in 1 ml of the homogenization medium.
  • the concentration of proteins in the resulting suspension was determined by Lowry's method and then adjusted to 4 to 8 mg/ml .
  • the resulting suspension was stored in a deep freezer (Biofreezer, Forma Scientific Inc. ) .
  • Horticulture and Animal Husbandry College, Korea each weighing about 2.5 to 2.6 kg were bred under a condition of temperature 2012°C, relative humidity 5515 %, and photoperiod 12L/12D.
  • the rabbits were divided by a group of 6 rabbits, and the rats of four groups were fed with four different diets, i.e., RC4 diet (Oriental Yeast Co., Japan) containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Merck, U. S. . ) (Comparative group); 1 % cholesterol plus 0.1 % hesperidin; and 1 % cholesterol plus 0.1 % hesperetin, respectively.
  • RC4 diet Oriental Yeast Co., Japan
  • RC4 diet comprises 7.6 % moisture, 22.8 % crude protein, 2.8 % crude fat, 8.8 % crude ash, 14.4 % crude cellulose and 43.6 % soluble nitrogen-free substances .
  • the rabbits were bred for 6 weeks while being allowed free access to the diets and water.
  • Step 2 Analysis for fatty streak in the main artery
  • the rabbits bred in (Step 1) were sacrificed and their chest were incised.
  • the main artery was cut out therefrom in a length of about 5 cm downward from the site 1 cm above the aortic valve and the fat surrounding the main artery was removed.
  • the main artery was incised in the middle along the longitudinal axis and pinned to a dish.
  • the moist artery was photographed and, then, staining of fatty streak was carried out in accordance with the method of Esper, E., et al. (J. Lab. Clin. Med. , 121, 103-110(1993)) as follows.
  • a part of the incised main artery was washed three times by 2 min. with anhydrous propylene glycol and stained for 30 min. with a saturated solution of Oil Red 0(0R0, Sigma Co.) dissolved in propylene glycol. Thereafter, the artery was washed twice by 3 min. with 85 % propylene glycol to remove remaining staining solution and, then washed with physical saline. The artery was photographed and the photograph was traced. The area of stained region (fatty streak region) was determined with an image analyzer (LEICA, Q-600, Germany) and its proportion(%) to the total arterial area was calculated.
  • the other part of the main artery was stained in accordance with hematoxylin-eosin(H&E) and Masson's trichrome staining methods and observed under a microscope to confirm whether the macrophage-lipid complexes were accumulated in the intima, internus, elastic lamina and media.
  • M-L complex Macrophage-lipid complex
  • the area of macrophage- lipid complex accumulated on the arterial endothelium decreased significantly in the 1 mg/kg Lovastatin® and 0.1 % hesperidin, 0.1 % hesperetin groups, as compared to the control group. Accordingly, it has been confirmed that hesperidin and hesperetin inhibit the accumulation of macrophage-lipid complex on the arterial endothelium. In particular, it is remarkable that the inhibitory activity of hesperidin and hesperetin on the accumulation of macrophage- lipid complex was exhibited under the blood cholesterol levels above 1,100 mg/dl, which are much higher than that of normal rabbit, i.e., about 50 mg/dl.
  • Figs. 1A, IB and 1C show the arteries of the rabbits administered with 1 % cholesterol (control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively.
  • a thick layer of macrophage- lipid complex was observed on the arterial endothelium of the rabbit administered with 1 % cholesterol, while no or very thin layers of macrophage-lipid complex were observed on the arterial endotheliums of the rabbits administered with 1 % cholesterol plus 1 mg/kg Lovastatin®, and 1 % cholesterol plus 0.1 % hesperidin, respectively.
  • mice 20 four-week-old Sprague-Dawley rats(Taihan laboratory animal center, Korea) each weighing about 90 to 110 g were evenly divided into two dietary groups by a randomized block design.
  • the rats of the two groups were fed with two different high-cholesterol diets, i.e., AIN-76 laboratory animal diet(ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol (Control group), and 1 % cholesterol plus 0.04% hesperidin, respectively.
  • the compositions of the diets fed to the two groups are shown in Table VI. Table VI
  • the rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the two groups in terms of the feed ingestion amount and the weight gain.
  • Step 2 Determination of serum GOT and GPT levels
  • GOT glutamate-oxaloacetate transaminase
  • GPT glutamate-pyruvate transaminase
  • Step 1 The same procedure as in ( Step 1 ) was repeated except that 30 three-month old New Zealand White rabbits (Yeonam Horticulture and Animal Husbandry College, Korea) each weighing about 2.5 to 2.6 kg were used in place of the rats, and the rabbits were fed for six weeks with three different diets, i.e., RC4 diet containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively.
  • RC4 diet containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively.
  • livers were separated from the rabbits and the histopathological observations were carried out as follows .
  • the rabbits were anesthetized with an intramuscular injection of ketamine(75 mg/kg) and subjected to an abdominal incision.
  • the color and degree of sclerosis of the liver were observed with eyes, and the liver separated from the rabbit was fixed in 10 % neutral buffered formalin for more than 24 hours.
  • the fixed liver was washed sufficiently with water, dehydrated stepwise with 70 %, 80 %, 90 % and 100 % ethanol and, then, embedded in paraffin.
  • the embedded liver was sectioned in 4 ⁇ m thickness with a microtome and stained with hematoxylin and eosin.
  • the stained liver specimen was made transparent with xylene, mounted with permount, and then observed under a microscope to confirm the presence of lesions.
  • Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1 % cholesterol (control group), 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group), and 1 % cholesterol plus 0.1 % hesperidin, respectively.
  • the hepatic cells of the control group and the comparative group are irregularly arranged and enlarged and a large amount of fat is deposited therein.
  • the hepatic cells of hesperidin group are normal and the deposition of fat is not observed. 'his result shows that hesperidin strongly inhibit the occurrence of fatty liver without toxic adverse effect to the hepatic cells .
  • Hesperidin was orally administered to a 55-year-old man at a daily dose of 10 mg/kg for 68 days and serum GOT, GPT and ⁇ GTP levels were determined just before the administration (day 0), and 45 and 68 days after the administratio (day 45 and day 68), respectively. Consequently, serum GOT levels at day 45 end day 68 decreased by 17 %, respectively, in comparison to that of day 0. Serum GPT levels at day 45 and day 68 decreased by 15 % and 19 %, respectively, in comparison to that of day 0. Further, serum ⁇ GTP levels at day 45 and day 68 decreased by 25 % and 51 %, respectively, in comparison to that of day 0.
  • hesperidin or hesperetin has a strong liver-protective activity and preventive activity on the hepatic diseases such as hepatitis, fatty liver and alcoholic fatty liver.
  • hesperidin was orally administered to a 56-year-old man, who had drunk alcoholic beverages habitually in an amount of 100 cc per day, at a daily dose of 6 mg/kg for 30 days and serum ⁇ GTP level was determined just before the administration (day 0) and 30 days after the administration (day 30). Consequently, initial serum ⁇ GTP level at day 0 was 129 IU/1, while that of day 30 decreased to 69 IU/1 which is within the normal range. This result demonstrates that hesperidin or hesperetin has a high activity of preventing alcoholic fatty liver and hepatocirrhosis .
  • Example 9 Foods containing Hesperidin or hesperetin
  • Foods containing hesperidin or hesperetin wore prepared as follows.
  • Hesperidin or hesperetin was added to a wheat flour in an amount ranging from 0.01 to 5 wt% and breads, cakes, cookies, crackers and noodles were prepared by using the mixture to obtain health-improving foods.
  • Hesperidin or hesperetin was added to soups and gravies in an amount ranging from 0.01 to 5 wt% to obtain health- improving soups and gravies .
  • Hesperidin or hesperetin was added to ground beef in an amount ranging from 0.01 to 5 wt% to obtain a health- improving ground beef.
  • Hesperidin or hesperetin was added to milk in an amount ranging from 0.01 to 5 wt% and various dairy products such as butter and ice cream were prepared by using the milk.
  • hesperidin or hesperetin was added to the coagulated milk protein; and, in case of yogurt preparation, hesperidin or hesperetin was added to the coagulated milk protein obtained after the fermentation.
  • Example 10 Beverages containing Hesperidin or hesperetin

Abstract

The present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.

Description

HESPERIDIN AND HESPERETIN AS INHIBITOR OF ACYL COA- CHOLESTEROL-O-ACYLTRANSFERASE, INHIBITOR OF MACROPHAGE- LIPID COMPLEX ACCUMULATION ON THE ARTERIAL WALL AND PREVENTIVE OR TREATING AGENT FOR HEPATIC DISEASES
FIELD OF THE INVENTION
The present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA- cholesterol-o-acyltransferase (ACAT), inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.
BACKGROUND OF THE INVENTION
In recent years, coronary cardio-circulary diseases, e.g., atherosclerosis and hypercholesterolemia, have increasingly become a major cause of deaths. It has been reported that an elevated plasma cholesterol level causes the deposition of fat, macrophages and foam cells on the wall of blood vessels, such deposit leading to plaque formation and then to atherosclerosis (Ross, R. , Nature , 362 , 801-809(1993)). One of the methods for decreasing the plasma cholesterol level is alimentotherapy to reduce the ingestion of cholesterol and lipids. Another method is to inhibit the absorption of cholesterol by inhibiting enzymes involved therein.
Acyl CoA-cholesterol-o-acyltransferase(ACAT) promotes the esterification of cholesterol in blood. Foam cells are formed by the action of ACAT and contain a large amount of cholesterol ester carried by low density lipoproteins . The formation of foam cells on the wall of artery increases with the ACAT activity, and, accordingly, an inhibitor of ACAT may also be an agent for preventing atherosclerosis. Further, it has been reported that the blood level of LDL- cholesterol can be reduced by inhibiting the ACAT activity(Witiak, D. T. and D. R. Feller (eds .) , Anti- Lipidemic Drugs; Medicinal, Chemical and Biochemical Aspects, Elsevier, ppl59-195 ( 1991 ) ) .
On the other hand, deterioration of hepatic functions may occur due to an excessive intake of alcohol or foods having a high lipid content, or an infection of hepatitis B or C virus, and it may develop into hepatitis, hepatocirrhosis or hepatic cancer. In particular, the excessive intake of fat-containing foods and alcohol causes fatty liver wherein a large amount of lipids is deposited in the liver tissue and the levels of serum GOT(glutamate- oxaloacetate transaminase) , GPT(glutamate-pyruvate transaminase) and γ-GTP(γ-glutamyl transpeptidase) are elevated(T. Banciu et al . , Med. Interne. , 20, 69-71(1982); and A. Par et al., Acta. Med. Acad. Sci. Hung., 33, 309- 319(1976) ) .
Numerous efforts have been made to develop medicines which inhibit ACAT activity; and, as a result, several compounds isolated from the cultures of various microorganisms have been reported. Examples of such compounds include pyripyropenes isolated from the culture of Aspergillus fumigatus ( S . Omura et al., J. Antibiotics, 46, 1168-1169(1993)) and Acaterin isolated from Pseudomonas sp.(S. Nagamura et al., J. Antibiotics, 45 , 1216- 1221(1992)).
Further, as a treating agent for hypercholesterolemia, a HMG-CoA reductase inhibitor named Lovastatin® has been developed and marketed by Merck Co., U.S.A. However, this medicine is known to induce adverse side effect of increasing creatin kinase in the liver.
Accordingly, there has continued to exist a need to develop non-toxic inhibitors of ACAT and macrophage-lipid complex accumulation on the arterial epithelium, and a preventive or treating agent for the hepatic diseases. The present inventors have endeavored to develop a novel and potent ACAT inhibitor, macrophage-lipid complex accumulation inhibitor and treating agent for the hepatic diseases from natural materials, and, as a result, have discovered that hesperidin or hesperetin has a potent ACAT inhibitory activity, macrophage-lipid complex accumulation inhibitory activity, and- preventive or treating activity on the hepatic diseases.
Hesperidin (C28H34015, M.W. : 610.55) and the aglycon of hesperidin, hesperetin (C16H1406, M.W. : 302.27), are flavonoids found in lemons, grapefruits, tangerines, citrons and oranges (Citrus sinensis) (Horowitz, Gentili, Tetrahedron, 19 , 773(1943)).
It has been reported that hesperidin or hesperetin has capillary-enhancing, permeability-reducing, anti-platelet aggregation, anti-inflammation, anti-viral, and blood- pressure and cholesterol lowering activities (Meyer, 0. C, Angiology, 45, 579-584(1994); Struck ann, J. R. , et al . , Angiol. , 45, 419-428(1994); Matsubara, Y., et al . , Japan Organic Synthesis Chem. Association Journal, 52 , 318-327(1994. Mar.); Galati, E. M. , et al., Farmaco . , 51(3), 219-221(1996, Mar.); Monforte, M. T., et al., Farmaco . , 5_0(9), 595-599(1995, Sep.); JP 95-86929; JP 95-86930; Chung, M. I., et al . , Chin. Pharm. J. (Taipei)., 46, 429-437(1994, Nov.); Galati, E. M. , et al . , Farmaco . , 4J)(11), 709-712(1994, Nov.); and Emim, J. A., et al . , J. Pharm. Pharmacol. , 4_6(2), 118-122(1994)). Further, Hesperidin has been used for the prevention and treatment of cerebral anemia, retinal hemorrhage and pelioma.
However, hitherto, none of the ACAT inhibitory activity, macrophage-lipid complex accumulation inhibitory activity and preventive or treating activity on the hepatic diseases of hesperidin or hesperetin has been reported.
SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide a novel use of hesperidin or hesperetin for inhibiting the ACAT activity in a mammal . Another object of the present invention is to provide a novel use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the endothelial wall of an artery in a mammal.
A further object of the present invention is to provide a novel use of hesperidin or hesperetin for preventing or treating hepatic diseases in a mammal.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which: Figs. 1A, IB and 1C show the arteries of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively; and
Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with one aspect of the present invention, there is provided a use of hesperidin or hesperetin for inhibiting the acyl-CoA cholesterol-o-acyltransferase (ACAT) activity in a mammal. In accordance with another aspect of the present invention, there is provided a use of hesperidin or hesperetin for inhibiting the accumulation of macrophage- lipid complex on the endothelial wall of an artery in a mammal . In accordance with a further aspect of the present invention, there is provided a use of hesperidin or hesperetin for preventing or treating hepatic diseases in a mammal .
Hesperidin and hesperetin may be extracted from the peel of citrus or synthesized according to the process described by Zemplen, Bognar, Ber . , 75 , 1043(1943) and Seka, Prosche, Monatsh. , 69 , 284(1936). Further, hesperetin can be prepared by the hydrolysis of hesperidin.
Hesperidin or hesperetin exerts an inhibitory effect on the ACAT activity and the accumulation of macrophage-lipid complex on the endothelial wall of an artery, and a preventive or treating effect on hepatic diseases at a dose of 0.1 mg/kg/day or more, the inhibitory effect increasing with the dose thereof.
Moreover, in spite of its potent efficacies, hesperidin or hesperetin shows little toxicity or mitogenicity in tests using mice. More specifically, hesperidin or hesperetin exhibits no toxicity when it is orally administered to a mouse at a dose of 100 mg/kg, which corresponds to an oral administration dose of 3 to 10 g/kg body weight of hesperidin or hesperetin for a person weighing 50 kg. Further, hesperidin and hesperetin exert no adverse effects on the liver function.
The present invention also provides a pharmaceutical composition for inhibiting the ACAT activity and accumulation of macrophage-lipid complex on the endothelial wall of an artery, and for preventing or treating hepatic diseases, which comprise hesperidin or hesperetin as an active ingredient and pharmaceutically acceptable excipients, carriers or diluents.
A pharmaceutical formulation may be prepared in accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient. Thus, the formulations may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like. Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoates, propylhydroxybenzoates , talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.
The pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction. In case of human, a typical daily dose of hesperidin or hesperetin may range from about 0.1 to 100 mg/kg body weight, preferably 3 to 10 mg/kg body weight, and can be administered in a single dose or in divided doses.
However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.
Moreover, hesperidin or hesperetin can be incorporated in foods or beverages, as an additive or a dietary supplement, for the purpose of inhibiting the ACAT activity, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium and/or preventing or treating hepatic diseases. The foods or beverages may include meats; juices such as a vegetable juice(e.g., carrot juice and tomato juice) and a fruit juice(e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice); chocolates; snacks; confectionery; pizza; foods made from cereal flour such as breads, cakes, crackers, cookies, biscuits, noodles and the likes; gums; dairy products such as milk, cheese, yogurt and ice creams; soups; broths; pastes, ketchups and sauces; teas; alcoholic beverages; carbonated beverages such as Coca-Cola® and Pepsi-Cola®; vitamin complexes; and various health foods.
In this case, the content of hesperidin or hesperetin in a food or beverage may range from 0.01 to 5% by weight. In particular, the beverage according to the present invention may comprise 200 to 10,000 mg of hesperidin or hesperetin per 1000 ml of the beverage.
As described above, hesperidin or hesperetin can be used as an effective, non-toxic pharmaceutical agent for inhibiting ACAT activity, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and/or preventing or treating hepatic diseases.
The following Examples are intended to further illustrate the present invention without limiting its scope. Further, percentages given below for solid in solid mixture, liquid in liquid, and solid in liquid are on a wt/wt, vol/vol and wt/vol basis, respectively, and all the reactions were carried out at room temperature, unless specifically indicated otherwise.
Example 1 : Extraction of Hesperidin from Citrus Peel
The peels of tangerines (Cheju Island, Korea), citrons (Jeollanamdo, Korea), and oranges, grapefruits and lemons (California, CA, U.S.A.) were dried at a room temperature and powdered to a particle size ranging from 100 to 200 μm. 50 iruβ of methanol was added to 500 mg each of the citrus peel powder and extracted in a water bath at 50 °C for 6 hours. The extract thus obtained was cooled and filtered, and then methanol was added to the filtrate to a volume of 50 m£ . To confirm the content of hesperidin in the extract obtained above, 5.0 μϋ of the resulting extract was subjected to high performance liquid chromatography(HPLC) using Lichrosorb RP-8 column(5 μm, 4 x 250 mm) which was pre-equilibrated with 37 % methanol and maintained at a temperature of 30°C. The extract was eluted with 37 % methanol at a flow rate of 1.0 mi/min. Standard solutions were prepared by dissolving hesperidin ( Sigma Chemical Co. U.S.A.) in methanol to final concentrations of 0.1, 0.2, 0.3, 0.4 and 0.5 mg/mi. , and subjected to HPLC under the same condition as above. The eluates were detected at 280 nm with UV-VIS spectrophotometer and the content of hesperidin was calculated by comparing the areas of HPLC profiles of the citrus peel extract and the standard solution. The content(%) of hesperidin in various citrus peel extracts is shown in Table I.
Table I
Figure imgf000010_0001
Example 2 : Toxicity of Orally Administered Hesperidin or Hesperetin
7 to 8 week-old, specific pathogen-free ICR female mice (6 heads) each weighing about 25 to 29 g and male mice (6 heads) each weighing about 34 to 38 g were bred under a condition of temperature 22±1°C, moisture 55±5 % and photoperiod 12L/12D. Fodder(Cheiljedang Co., mouse and rat fodder) and water were sterilized and fed to the mice. Hesperidin or hesperetin was dissolved in 0.5 % Tween 80 to a concentration of 100 mg/ml , and the solution was orally administered to the mice in an amount of 0.2 ml per 20 g of mouse body weight. The solution was administered once and the mice were observed for 10 days for signs of adverse effects or death according to the following schedule: 1, 4, 8, and 12 hours after the administration and, every 12 hours thereafter. The weight changes of the mice were recorded every day to examine the effect of hesperidin or hesperetin. Further, on the 10th day, the mice were sacrificed and the internal organs were visually examined.
All the mice were alive at day 10 and hesperidin or hesperetin showed no toxicity at a dose of 1,000 mg/kg. The autopsy revealed that the mice did not develop any pathological abnormality, and no weight loss was observed during the 10 day test period. Accordingly, it was concluded that hesperidin or hesperetin is not toxic when orally administered to an animal.
Example 3 : Administration of Hesperidin or Hesperetin to an Animal
30 four-week-old Sprague-Dawley rats(Taihan laboratory animal center, Korea) each weighing about 90 to 110 g were evenly divided into three dietary groups by a randomized block design. The rats of the three groups were fed with three different high-cholesterol diets, i.e., AIN-76 laboratory animal diet(ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol (Control group), and 1 % cholesterol plus 0.1% hesperidin or hesperetin, respectively. The compositions of diets fed to the three groups are shown in Table II. Table II
Figure imgf000012_0001
Purchased from TEKLAD premier Co. (Madison, WI, U.S.A.)
The rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the three groups in terms of the feed ingestion amount and the weight gain.
Example 4 : Determination of Total Cholesterol, HDL-
Cholesterol and Neutral Lipid Content in Plasma
The effect of administering hesperidin or hesperetin to rats on the plasma cholesterol and neutral lipid content was determined as follows.
Blood samples were taken from the rats of the three dietary groups and plasma HDL fractions were separated therefrom by using HDL-cholesterol reagent ( Sigma Chemical Co., Cat. No. 352-3) containing dextran-sulfate . Total cholesterol and HDL-cholesterol levels were determined by using Sigma Diagnostic Kit Cat. No. 352-100 ( Sigma Chemical Co. , U.S.A. ) (Allain et al . , Clin. Chem. , 20, 470-475(1974) ) . Neutral lipid level was determined by using Sigma Diagnostic Kit Cat. No. 339-50(Bucolo, G. and David, H. , Clin. Chem. , 19, 476-482(1973)). The result is shown in Table III, wherein the total plasma cholesterol levels in hesperidin and hesperetin-fed rat groups decreased by 11 % and 15%, respectively, as compared with that of the control group.
Table III
Figure imgf000013_0001
* Total-C: Total-cholesterol
* HDL-C: HDL-cholesterol
* TG: Triglyceride
Example 5 : Activity of Hesperidin and Hesperetin in ACAT
Inhibition
(Step 1) Preparation of microsomes
To determine the effects of hesperidin and hesperetin feeding to rats on the activity of ACAT, microsomes were separated from the liver tissue to be used as an enzyme source.
First, the rats of the three groups prepared in Example 3 were sacrificed by decapitation and the livers were excised. 1 g each of the livers was homogenized in 5 ml of homogenization medium(0.1 M KH2P04, pH 7.4 , 0.1 mM EDTA and 10 mM β-mercaptoethanol) . The homogenate was centrifuged at 3,000xg for 10 min. at 4°C and the supernatant thus obtained was centrifuged at 15,000xg for 15 min. at 4°C to obtain a supernatant. The supernatant was put into an ultracentrifuge tube(Beckman) and centrifuged at 100,000xg for 1 hour at 4°C to obtain microsomal pellets, which were then suspended in 3 ml of the homogenization medium and centrifuged at 100,000xg for 1 hour at 4°C. The pellets thus obtained were suspended in 1 ml of the homogenization medium. The concentration of proteins in the resulting suspension was determined by Lowry's method and then adjusted to 4 to 8 mg/ml . The resulting suspension was stored in a deep freezer (Biofreezer, Forma Scientific Inc. ) .
(Step 2) ACAT assay
6.67 μl of 1 mg/ml cholesterol solution in acetone was mixed with 6 μl of 10 % Triton WR-1339 (Sigma Co.) in acetone and, then, acetone was removed from the mixture by evaporation using nitrogen gas. Distilled water was added to the resulting mixture in an amount to adjust the concentration of cholesterol to 30 mg/ml.
To 10 μl of the resulting aqueous cholesterol solution were added 10 μl of 1 M KH2P04(pH 7.4), 5 μl of 0.6 mM bovine serum albumin(BSA) , 10 μl of microsome solution obtained in (Step 1) and 55 μl of distilled water(total 90 μl). The mixture was pre-incubated in a waterbath at 37 °C for 30 min.
10 μl of (1-14C) oleoyl-CoA solution(0.05 μCi, final concentration: 10 μM) was added to the pre-incubated mixture and the resulting mixture was incubated in a waterbath at
37 °C for 30 min. To the mixture were added 500 μl of isopropanol : heptane mixture(4 : 1 (v/v) ) , 300 μl of heptane and 200 μl of 0.1 M KH2POA(pH 7.4), and the mixture was mixed violently by using a vortex and then allowed to stand at a room temperature for 2 min.
200 μl of the resulting supernatant was put in a scintillation bottle and 4 ml of scintillation fluid(Lumac) was added thereto. The mixture was assayed for radioactivity with 1450 Microbeta liquid scintillation counter (Wallacoy, Finland). ACAT activity was calculated as picomoles of cholesteryl oleate synthesized per min. per mg protein(pmoles/min/mg protein) . The result is shown in Table IV.
Table IV
Figure imgf000015_0001
As can be seen from Table IV, ACAT activities observed in hesperidin and hesperetin-fed rat groups are lower than that of the control group by 19.2% and 23.5%, respectively.
Example 6 : Inhibition of Plaque Formation Caused by
Macrophage-Lipid Complex in Hesperidin and Hesperetin-Fed Animals
(Step 1) Administration of hesperidin and hesperetin to animals
24 three-month-old New Zealand White rabbits (Yeonam
Horticulture and Animal Husbandry College, Korea) each weighing about 2.5 to 2.6 kg were bred under a condition of temperature 2012°C, relative humidity 5515 %, and photoperiod 12L/12D. The rabbits were divided by a group of 6 rabbits, and the rats of four groups were fed with four different diets, i.e., RC4 diet (Oriental Yeast Co., Japan) containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Merck, U. S. . ) (Comparative group); 1 % cholesterol plus 0.1 % hesperidin; and 1 % cholesterol plus 0.1 % hesperetin, respectively. RC4 diet comprises 7.6 % moisture, 22.8 % crude protein, 2.8 % crude fat, 8.8 % crude ash, 14.4 % crude cellulose and 43.6 % soluble nitrogen-free substances . The rabbits were bred for 6 weeks while being allowed free access to the diets and water.
(Step 2) Analysis for fatty streak in the main artery
The rabbits bred in (Step 1) were sacrificed and their chest were incised. The main artery was cut out therefrom in a length of about 5 cm downward from the site 1 cm above the aortic valve and the fat surrounding the main artery was removed. The main artery was incised in the middle along the longitudinal axis and pinned to a dish. The moist artery was photographed and, then, staining of fatty streak was carried out in accordance with the method of Esper, E., et al. (J. Lab. Clin. Med. , 121, 103-110(1993)) as follows.
A part of the incised main artery was washed three times by 2 min. with anhydrous propylene glycol and stained for 30 min. with a saturated solution of Oil Red 0(0R0, Sigma Co.) dissolved in propylene glycol. Thereafter, the artery was washed twice by 3 min. with 85 % propylene glycol to remove remaining staining solution and, then washed with physical saline. The artery was photographed and the photograph was traced. The area of stained region (fatty streak region) was determined with an image analyzer (LEICA, Q-600, Germany) and its proportion(%) to the total arterial area was calculated.
On the other hand, the other part of the main artery was stained in accordance with hematoxylin-eosin(H&E) and Masson's trichrome staining methods and observed under a microscope to confirm whether the macrophage-lipid complexes were accumulated in the intima, internus, elastic lamina and media.
Further, blood samples were taken from the rabbits and total cholesterol and triglyceride levels were determined in accordance with the same procedure in Example 4.
The result is shown in Table V.
Table V
Figure imgf000017_0001
M-L complex: Macrophage-lipid complex
As can be seen from Table V, the area of macrophage- lipid complex accumulated on the arterial endothelium decreased significantly in the 1 mg/kg Lovastatin® and 0.1 % hesperidin, 0.1 % hesperetin groups, as compared to the control group. Accordingly, it has been confirmed that hesperidin and hesperetin inhibit the accumulation of macrophage-lipid complex on the arterial endothelium. In particular, it is remarkable that the inhibitory activity of hesperidin and hesperetin on the accumulation of macrophage- lipid complex was exhibited under the blood cholesterol levels above 1,100 mg/dl, which are much higher than that of normal rabbit, i.e., about 50 mg/dl. This result suggests that there may be a novel mechanism for preventing the onset of atherosclerosis, which is different from the blocking of cholesterol synthesis by a HMG-CoA reductase inhibitor, blocking of cholesterol absorption by an ACAT inhibitor, or blocking of cholesterol transfer by a CETP inhibitor.
Figs. 1A, IB and 1C show the arteries of the rabbits administered with 1 % cholesterol (control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively. As shown in Figs. 1A, IB and 1C, a thick layer of macrophage- lipid complex was observed on the arterial endothelium of the rabbit administered with 1 % cholesterol, while no or very thin layers of macrophage-lipid complex were observed on the arterial endotheliums of the rabbits administered with 1 % cholesterol plus 1 mg/kg Lovastatin®, and 1 % cholesterol plus 0.1 % hesperidin, respectively.
Accordingly, it has been concluded that hesperidin and hesperetin strongly inhibit the accumulation of macrophage- lipid complex on the arterial endothelium.
Example 7 : Prevention of Hepatic Diseases by Hesperidin
(Step 1) Administration of hesperidin to rats
20 four-week-old Sprague-Dawley rats(Taihan laboratory animal center, Korea) each weighing about 90 to 110 g were evenly divided into two dietary groups by a randomized block design. The rats of the two groups were fed with two different high-cholesterol diets, i.e., AIN-76 laboratory animal diet(ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol (Control group), and 1 % cholesterol plus 0.04% hesperidin, respectively. The compositions of the diets fed to the two groups are shown in Table VI. Table VI
Figure imgf000019_0001
* Purchased from TEKLAD premier Co. (Madison, WI, U.S.A.)
The rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the two groups in terms of the feed ingestion amount and the weight gain.
(Step 2) Determination of serum GOT and GPT levels
The effect of administering hesperidin to rats on the function of the liver was examined as follows .
Blood samples were taken from the rats of the two dietary groups and serum GOT(glutamate-oxaloacetate transaminase) and GPT(glutamate-pyruvate transaminase) levels were determined in accordance with the method of Reitman and Frankel(Reitman, S. and J. S. Frankel, Am. J. Clin. Pathol. , 28, 56(1956)). GOT and GPT are synthesized in the liver and heart, and released into blood stream upon the damage of these organs. Accordingly, GOT and GPT are representative markers of the liver-function and high serum GOT and GPT levels mean severe damage of the liver.
The result showed that GOT and GPT levels of hesperidin group were lower than those of the control group by about 30 % and 10 %, respectively.
(Step 3) Experiment using rabbits
The same procedure as in ( Step 1 ) was repeated except that 30 three-month old New Zealand White rabbits (Yeonam Horticulture and Animal Husbandry College, Korea) each weighing about 2.5 to 2.6 kg were used in place of the rats, and the rabbits were fed for six weeks with three different diets, i.e., RC4 diet containing 1 % cholesterol (Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively.
Thereafter, the livers were separated from the rabbits and the histopathological observations were carried out as follows .
The rabbits were anesthetized with an intramuscular injection of ketamine(75 mg/kg) and subjected to an abdominal incision. The color and degree of sclerosis of the liver were observed with eyes, and the liver separated from the rabbit was fixed in 10 % neutral buffered formalin for more than 24 hours. The fixed liver was washed sufficiently with water, dehydrated stepwise with 70 %, 80 %, 90 % and 100 % ethanol and, then, embedded in paraffin. The embedded liver was sectioned in 4 μm thickness with a microtome and stained with hematoxylin and eosin. The stained liver specimen was made transparent with xylene, mounted with permount, and then observed under a microscope to confirm the presence of lesions.
Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1 % cholesterol (control group), 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group), and 1 % cholesterol plus 0.1 % hesperidin, respectively. As shown in Figs. 2A and 2B, the hepatic cells of the control group and the comparative group are irregularly arranged and enlarged and a large amount of fat is deposited therein. In contrast, as shown in Fig. 2C, the hepatic cells of hesperidin group are normal and the deposition of fat is not observed. 'his result shows that hesperidin strongly inhibit the occurrence of fatty liver without toxic adverse effect to the hepatic cells .
(Step 4) Experiment using human
Hesperidin was orally administered to a 55-year-old man at a daily dose of 10 mg/kg for 68 days and serum GOT, GPT and γGTP levels were determined just before the administration (day 0), and 45 and 68 days after the administratio (day 45 and day 68), respectively. Consequently, serum GOT levels at day 45 end day 68 decreased by 17 %, respectively, in comparison to that of day 0. Serum GPT levels at day 45 and day 68 decreased by 15 % and 19 %, respectively, in comparison to that of day 0. Further, serum γGTP levels at day 45 and day 68 decreased by 25 % and 51 %, respectively, in comparison to that of day 0. Surprisingly, reduction of serum γGTP level at day 68 was more than 50 %, and this result suggests that hesperidin or hesperetin has a strong liver-protective activity and preventive activity on the hepatic diseases such as hepatitis, fatty liver and alcoholic fatty liver.
On the other hand, hesperidin was orally administered to a 56-year-old man, who had drunk alcoholic beverages habitually in an amount of 100 cc per day, at a daily dose of 6 mg/kg for 30 days and serum γGTP level was determined just before the administration (day 0) and 30 days after the administration (day 30). Consequently, initial serum γGTP level at day 0 was 129 IU/1, while that of day 30 decreased to 69 IU/1 which is within the normal range. This result demonstrates that hesperidin or hesperetin has a high activity of preventing alcoholic fatty liver and hepatocirrhosis .
Example 9 : Foods containing Hesperidin or hesperetin
Foods containing hesperidin or hesperetin wore prepared as follows.
( 1 ) Preparation of tomato ketchup and sauce Hesperidin or hesperetin was added to a tomato ketchup or sauce in an amount ranging from 0.01 to 5 wt% to obtain a health-improving tomato ketchup or sauce.
(2) Preparation of wheat flour foods
Hesperidin or hesperetin was added to a wheat flour in an amount ranging from 0.01 to 5 wt% and breads, cakes, cookies, crackers and noodles were prepared by using the mixture to obtain health-improving foods.
( 3 ) Preparation of soups and gravies
Hesperidin or hesperetin was added to soups and gravies in an amount ranging from 0.01 to 5 wt% to obtain health- improving soups and gravies .
(4) Preparation of ground beef
Hesperidin or hesperetin was added to ground beef in an amount ranging from 0.01 to 5 wt% to obtain a health- improving ground beef.
(5) Preparation of dairy product
Hesperidin or hesperetin was added to milk in an amount ranging from 0.01 to 5 wt% and various dairy products such as butter and ice cream were prepared by using the milk.
However, in case of cheese preparation, hesperidin or hesperetin was added to the coagulated milk protein; and, in case of yogurt preparation, hesperidin or hesperetin was added to the coagulated milk protein obtained after the fermentation.
Example 10: Beverages containing Hesperidin or hesperetin
(1) Preparation of vegetable juice
200 to 10,000 mg of hesperidin or hesperetin was ddded to 1000 m of a tomato or carrot Juice to obtain a health- improving vegetable juice.
(2) Preparation of fruit juice
200 to 10,000 mg of hesperidin or hesperetin was added to 1000 mi of an apple or grape Juice to obtain a health- improving fruit juice.
( 3 ) Preparation of carbonated drink
200 to 10,000 mg of hesperidin or hesperetin was added to 1000 mi of Coca-Cola® or Pepsi-Cola® to obtain a health- improving carbonated drink.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims .

Claims

What is claimed is :
1. A use of hesperidin or hesperetin for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase(ACAT) in a mammal .
2. The use of claim 1, wherein the mammal is human.
3. The use of claim 1, wherein hesperidin or hesperetin is administered to the mammal in the form of a composition containing same, said composition being selected from the group consisting of: a pharmaceutical composition, a food composition and a beverage composition.
4. The use of claim 3, wherein the effective amount of hesperidin or hesperetin contained in the pharmaceutical composition ranges from 0.1 to 100 mg/kg body weight/day.
5. The use of claim 3, wherein the content of hesperidin or hesperetin in the food composition ranges from
0.01 to 5% by weight.
6. The use of claim 3, wherein the food is meats, chocolates, snacks, confectionery, pizza, foods made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces, vitamin complexes or health foods.
7. The use of claim 6, wherein the foods made from cereal flour is breads, cakes, crackers, cookies, biscuits or noodles.
8. The use of claim 3, wherein the beverage composition is dairy products, vegetable juices, ."rruit juices, teas, alcoholic beverages or carbonated beverages.
9. The use of claim 3, wherein the content of hesperidin or hesperetin in the beverage composition ranges from 200 to 10,000 mg per 1,000 ml of the beverage.
10. A use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium in a mammal.
11. The use of claim 10, wherein the mammal is human.
12. The use of claim 10, wherein hesperidin or hesperetin is administered to the mammal in the form of a composition containing same, said composition being selected from the group consisting of: a pharmaceutical composition, a food compassion and a beverage composition.
13. The use of claim 12, wherein the effective amount of hesperidin or hesperetin contained in the pharmaceutical composition ranges from 0.1 to 100 mg/kg body weight/day.
14. The use of claim 12, wherein the content of hesperidin or hesperetin in the food composition ranges from
0.01 to 5% by weight.
15. The use of claim 12, wherein the food composition is meats, chocolates, snacks, confectionery, pizza, foods made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces, vitamin complexes or health foods.
16. The use of claim 15, wherein the foods made from cereal flour is breads, cakes, crackers, cookies, biscuits or noodles.
17. The use of claim 12, wherein the beverage composition is dairy products, vegetable juJce╬╡, fruit juices, teas, alcoholic beverages or carbonated beverages.
18. The use of claim 12, wherein the content of hesperidin or hesperetin in the beverage composition ranges from 200 to 10,000 mg per 1,000 ml of the beverage.
19. A use of hesperidin or hesperetin for preventing or treating a hepatic disease in a mammal.
20. The use of claim 19, wherein the mammal is human.
21. The use of claim 19, wherein hesperidin or hesperetin is administered to the mammal in the form of a composition being selected from the group consisting of: a pharmaceutical composition, a food composition and a beverage composition.
22. The use of claim 21, wherein the effective amount of hesperidin or hesperetin contained in the pharmaceutical composition ranges from 0.1 to 100 mg/kg body weight/day.
23. The use of claim 21, wherein the content of hesperidin or hesperetin in the food composition ranges from 0.01 to 5% by weight.
24. The use of claim 21, wherein the food composition is meats, chocolates, snacks, confectionery, pizza, foods made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces, vitamin complexes or health foods.
25. The use of claim 24, wherein the foods made from cereal flour is breads, cakes, crackers, cookies, biscuits or noodles.
26. The use of claim 21, wherein the beverage composition is dairy products, vegetable juices, fruit juices, teas, alcoholic beverages or carbonate beverages.
27. The use of claim 21, wherein the content of hesperidin or hesperetin in the beverage composition ranges from 200 to 10,000 mg per 1,000 ml of the beverage.
PCT/KR1998/000324 1997-10-28 1998-10-20 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases WO1999021549A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98951777A EP1063988A1 (en) 1997-10-28 1998-10-20 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
CA002307890A CA2307890A1 (en) 1997-10-28 1998-10-20 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
JP2000517707A JP2001520993A (en) 1997-10-28 1998-10-20 Acyl COA-cholesterol-O-acyltransferase inhibitors, inhibitors of macrophage-lipid complex accumulation on arterial walls and hesperidin and hesperetin as agents for preventing or treating liver diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR1997/55578 1997-10-28
KR1019970055578A KR19990034089A (en) 1997-10-28 1997-10-28 Acylcoay: Cholesterol-Ortho-Acyltransferase Inhibitor Compositions Including Hesperidin or Hesperetin
KR1998/10888 1998-03-28
KR1019980010888A KR19990076178A (en) 1998-03-28 1998-03-28 Composition for the prevention and treatment of liver disease, including hesperidin
KR1998/12411 1998-04-08
KR1019980012411A KR19990079683A (en) 1998-04-08 1998-04-08 Functional health food containing citrus rind powder or rind extract
KR1998/13283 1998-04-14
KR1019980013283A KR19990080214A (en) 1998-04-14 1998-04-14 Functional drink containing health extract of citrus peel

Publications (1)

Publication Number Publication Date
WO1999021549A1 true WO1999021549A1 (en) 1999-05-06

Family

ID=27483239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1998/000324 WO1999021549A1 (en) 1997-10-28 1998-10-20 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases

Country Status (5)

Country Link
EP (1) EP1063988A1 (en)
JP (1) JP2001520993A (en)
CN (1) CN1124133C (en)
CA (1) CA2307890A1 (en)
WO (1) WO1999021549A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032160A2 (en) * 1999-11-05 2001-05-10 Tropicana Products, Inc. Modification of cholesterol concentrations with citrus phytochemicals
FR2841472A1 (en) * 2002-06-28 2004-01-02 Agronomique Inst Nat Rech NUTRITIONAL OR THERAPEUTIC COMPOSITION CONTAINING THE HESPERIDINE COMPOUND OR ONE OF ITS DERIVATIVES
JP2007112806A (en) * 2006-11-27 2007-05-10 Kao Corp Agent for promoting body-fat burning
EP1792974A1 (en) * 2004-07-23 2007-06-06 Suntory Limited Alcohol-pickled material, food or drink using the same and method of producing the same
EP1987725A1 (en) * 2006-01-23 2008-11-05 Suntory Limited Food or drink and method of producing the same
EP2368442A2 (en) 2005-07-27 2011-09-28 Symrise AG Use of hesperetin for enhancing the sweet taste

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101356330B1 (en) 2004-12-24 2014-01-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Hepatic function remedial agent
JP2009007256A (en) * 2007-06-26 2009-01-15 Kao Corp Nadh/nadph oxidase inhibitor
CN104688756A (en) * 2013-12-09 2015-06-10 中国药科大学 Pharmaceutical composition and its use in preparation of drug for treating alcoholic liver injury
TWI715172B (en) * 2019-08-28 2021-01-01 健茂生物科技股份有限公司 Composition in suppressing body fat accumulation
CN114832007A (en) * 2021-02-01 2022-08-02 健茂生物科技股份有限公司 Composition for reducing cholesterol and preparation method thereof
CN114832041A (en) * 2021-02-01 2022-08-02 健茂生物科技股份有限公司 Composition with liver protection effect and preparation method thereof
CN115607538A (en) * 2022-09-26 2023-01-17 浙江工商大学 Application of hesperetin in preparation of medicine for inhibiting and/or treating wheat allergy

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54154569A (en) * 1978-05-20 1979-12-05 Lotte Co Ltd Chewing gum for sports
WO1989005141A1 (en) * 1987-12-10 1989-06-15 Tsumura Juntendo, Inc. Anti-retroviral drug
EP0347864A2 (en) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Anti-atherogenic agents
JPH04295428A (en) * 1991-03-22 1992-10-20 Dai Ichi Seiyaku Co Ltd Antiallergic agent
WO1994023717A1 (en) * 1993-04-20 1994-10-27 The Procter & Gamble Company Methods of using hesperetin for sebum control and treatment of acne
EP0633022A2 (en) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Chondroprotective flavones
JPH08280358A (en) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd Food effective for improving lipid metabolism and its production
JPH08283154A (en) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd Lipid metabolism improver

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150038A (en) * 1977-05-16 1979-04-17 Dynapol Conversion of hesperidin into hesperetin

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54154569A (en) * 1978-05-20 1979-12-05 Lotte Co Ltd Chewing gum for sports
WO1989005141A1 (en) * 1987-12-10 1989-06-15 Tsumura Juntendo, Inc. Anti-retroviral drug
EP0347864A2 (en) * 1988-06-24 1989-12-27 Andries Johannes Cornelus Strydom Anti-atherogenic agents
JPH04295428A (en) * 1991-03-22 1992-10-20 Dai Ichi Seiyaku Co Ltd Antiallergic agent
WO1994023717A1 (en) * 1993-04-20 1994-10-27 The Procter & Gamble Company Methods of using hesperetin for sebum control and treatment of acne
EP0633022A2 (en) * 1993-07-09 1995-01-11 Kureha Chemical Industry Co., Ltd. Chondroprotective flavones
EP0719554A1 (en) * 1993-07-09 1996-07-03 Kureha Chemical Industry Co., Ltd. Chondroprotective flavonoids
JPH08280358A (en) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd Food effective for improving lipid metabolism and its production
JPH08283154A (en) * 1995-04-12 1996-10-29 Nippon Shinyaku Co Ltd Lipid metabolism improver

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE WPIL ON QUESTEL, week 8003, LONDON: DERWENT PUBLICATIONS LTD., AN 80-04477C, Class A23G; & JP 54154569 A (LOTTE KK.) 05 December 1979. *
DATABASE WPIL ON QUESTEL, week 8926, LONDON: DERWENT PUBLICATIONS LTD., AN 89-192550, Class A61K; & WO 8905141 A (TSUMURA & CO.) 15 June 1989. *
DATABASE WPIL ON QUESTEL, week 9001, LONDON: DERWENT PUBLICATIONS LTD., AN 90-001242, Class A61B; & EP 0347864 A (STRYDOM A.J.C.) 27 December 1989. *
DATABASE WPIL ON QUESTEL, week 9248, LONDON: DERWENT PUBLICATIONS LTD., AN 92-395348, Class A61K; & JP 04295428 A (DAIICHI PHARM. CO., LTD.) 20 October 1992. *
DATABASE WPIL ON QUESTEL, week 9506, LONDON: DERWENT PUBLICATIONS LTD., AN 95-038283, Class A61K; & EP 0633022 A2 (KUREHA CHEM. IND. CO., LTD.) 11 January 1995. *
DATABASE WPIL ON QUESTEL, week 9631, LONDON: DERWENT PUBLICATIONS LTD., AN 96-302114, Class A61K; & EP 0719554 A1 (KUREHA CHEM. IND. CO., LTD.) 03 July 1996. *
DATABASE WPIL ON QUESTEL, week 9702, LONDON: DERWENT PUBLICATIONS LTD., AN 97-014823, Class A61K; & JP 08280358 A (NIPPON SHINYAKU CO., LTD.) 29 October 1996. *
DATABASE WPIL ON QUESTEL, week 9702, LONDON: DERWENT PUBLICATIONS LTD., AN 97-017298, Class A61K; & JP 08283154 A (NIPPON SHINYAKU CO., LTD.) 29 October 1996. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032160A2 (en) * 1999-11-05 2001-05-10 Tropicana Products, Inc. Modification of cholesterol concentrations with citrus phytochemicals
WO2001032160A3 (en) * 1999-11-05 2002-03-21 Tropicana Prod Inc Modification of cholesterol concentrations with citrus phytochemicals
FR2841472A1 (en) * 2002-06-28 2004-01-02 Agronomique Inst Nat Rech NUTRITIONAL OR THERAPEUTIC COMPOSITION CONTAINING THE HESPERIDINE COMPOUND OR ONE OF ITS DERIVATIVES
US8859612B2 (en) 2002-06-28 2014-10-14 Institut National De La Recherche Agronomique (Inra) Use of hesperidin or one of its derivatives for making a medicine for bone formation stimulation
EP1792974A1 (en) * 2004-07-23 2007-06-06 Suntory Limited Alcohol-pickled material, food or drink using the same and method of producing the same
EP1792974A4 (en) * 2004-07-23 2011-06-15 Suntory Holdings Ltd Alcohol-pickled material, food or drink using the same and method of producing the same
US8163319B2 (en) 2004-07-23 2012-04-24 Suntory Holdings Limited Method of production of an alcohol-dipped food or drink
EP2368442A2 (en) 2005-07-27 2011-09-28 Symrise AG Use of hesperetin for enhancing the sweet taste
EP1987725A1 (en) * 2006-01-23 2008-11-05 Suntory Limited Food or drink and method of producing the same
EP1987725A4 (en) * 2006-01-23 2011-12-07 Suntory Holdings Ltd Food or drink and method of producing the same
US8993024B2 (en) 2006-01-23 2015-03-31 Suntory Holdings Limited Food or drink and method of production thereof
JP2007112806A (en) * 2006-11-27 2007-05-10 Kao Corp Agent for promoting body-fat burning

Also Published As

Publication number Publication date
JP2001520993A (en) 2001-11-06
CA2307890A1 (en) 1999-05-06
CN1278170A (en) 2000-12-27
EP1063988A1 (en) 2001-01-03
CN1124133C (en) 2003-10-15

Similar Documents

Publication Publication Date Title
US6165984A (en) Naringin and naringenin as inhibitors of acyl CoA-cholesterol-o-acyltransferase
CA2307553C (en) Citrus peel extract as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
US6509372B2 (en) Method for preventing or treating elevated blood lipid level-related diseases by administering rutin and quercetin
US6133241A (en) Bioflavonoids as plasma high density lipoprotein level increasing agent
RU2203050C2 (en) Bioflavonoids as blood glucose level- decreasing agent
US20060040911A1 (en) Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus)
EP0957911B1 (en) HESPERIDIN AND HESPERETIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR
EP1063988A1 (en) Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
US20010002264A1 (en) Citrus peel extract as inhibitor of fatty streak formation on the arterial wall
EP1113726B1 (en) Use of neohesperidin dihydrochalcone for the manufacture of a medicament for preventing or treating elevated blood lipid level-related diseases
RU2197239C2 (en) Hesperidin and hesperetin as inhibitor of acyl-coa-cholesterol-o- acyltransferase, inhibitors of accumulation of complexes macrophage-lipid on artery walls and as agent for prophylaxis or treatment of diseases
RU2201228C2 (en) Naringin and naringenin as agents for prophylaxis or treatment of liver disease
EP1123096A1 (en) Bioflavonoids as plasma high density lipoprotein level increasing agent
KR20010015495A (en) Rutin and quercetin-containing composition for preventing and treating hyperlipidemia, artherosclerosis and hepatic disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98810701.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP RU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2307890

Country of ref document: CA

Ref document number: 2307890

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998951777

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998951777

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998951777

Country of ref document: EP